Short explainers on the provisions and judgement calls that come up most often. The full notes are being published progressively — if one of the summaries below covers a question you have now, call or email and we will talk it through.
The expanded set of prescribed methods for non-resident investment, the valuation-date window, the limited price-matching safe harbour, and the practical question of which route leaves you least exposed at assessment.
Stale financials, a valuation date that does not match the transaction, no statement of the methodology applied, missing workings, the wrong signatory, and conversion formulas that fail the pricing test.
Why the headline round price is not the value of an ordinary share, how liquidation preference and participation rights redistribute value, and what an option-pricing allocation actually does.
Valuation date versus allotment date, whether the report predates the board resolution, using a certificate issued for a different purpose, and the limits of a valuation's shelf life.
Separability and contractual-legal criteria, choosing between relief-from-royalty, MPEEM and with-and-without, and why a goodwill residual above 60% invites questions.
Ind AS 102 fair value at grant for the accounting charge, and Rule 3(8) fair market value at exercise for the perquisite. Different dates, different methods, different numbers.
What Regulations 27 and 35 actually require, why the two values answer different questions, and how the resolution professional should read a material divergence between the two valuers.
Risk-free rate selection, equity risk premium sources, beta from a peer set that barely exists, and the size and company-specific premiums that reviewers challenge most.
A structured critique: check the basis of value first, then the date, then the information relied upon, then the arithmetic. Most reports fail on one of the first three.
Ask it directly. If it is a common one, it becomes the next note.